Novo Nordisk A/S left open the door for additional work on its pill version of Ozempic for Alzheimer’s disease after a pair ...

High-sensitivity C-reactive protein (CRP) decreased significantly in the semaglutide group, with estimated treatment ratios ...

Tantalizing results from small trials and anecdotes raised hopes that drugs like Ozempic could help. Despite setbacks, ...

Researchers found long-term treatment could delay progression from mild cognitive impairment to moderate Alzheimer’s disease ...

An Alzheimer’s drug which has been rejected for NHS use can slow disease progression by eight years, researchers have claimed ...

GLP-1 drugs, which include Ozempic and Wegovy, have become one of the most closely watched experimental approaches for ...

The experimental drug neflamapimod reduced a key biomarker of neurodegeneration, which correlated with a slowing of cognitive ...

Discusses Clinical Progress of Lead Drug Candidates Targeting Parkinson's, Alzheimer's, and Liver Disease December 9, 2025 4:15 ...

It is widely known that Alzheimer's disease is mainly associated with the overproduction of β-amyloid peptides and damage ...

The spending watchdog deemed the drug's benefits 'too small' to justify the cost of making it available on the NHS ...

Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people ...